-
Should Beta-Blockers Remain First Choice in the Treatment of Primary Hypertension?; Obstructive Sleep Apnea as a Risk Factor for Stroke and Death; Cholinesterase Inhibitors for Alzheimers Disease
-
The majority of chronic stable coronary artery disease patients given 75 mg of EC aspirin daily have adequate inhibition of COX, but younger, heavier, and post MI patients may not.
-
Patients in an internal medicine outpatient clinic overwhelmingly preferred both male and female doctors in professional attire with a white coat, and were more willing to share their personal history with them.
-
The ECG in the Figure was obtained from a 77-year-old. woman with a history of "heart problems." What can (and can not) be said about this tracing?
-
-
Following a priority review, the FDA has approved deferasirox, the first oral iron chelator for the treatment of chronic iron overload due to transfusions. It will be marketed by Novartis Pharmaceuticals as Exjade®.
-
Patients who receive extended anticoagulation are protected from recurrent VTE while receiving long-term therapy. The clinical benefit is maintained after anticoagulation is discontinued, but the magnitude of the benefit is less pronounced.
-
Beta-Blockers Therapy for the Treatment of Hypertension; Treatments for Acute Migraine; Statin Therapy for ACS Patients; The Correct Dosing for Onychomycosis; FDA Actions
-
Tipranavir is a recently approved protease inhibitor for the treatment of HIV-1 infections. It is a selective non-peptide HIV-1 protease inhibitor for treatment-experienced adults with resistance to multiple protease inhibitors. Tipranavir is marketed by Boehringer Ingelheim as Aptivus®.
-
Cola consumption, but not caffeine per se, was associated with increased risk of developing hypertension over a 12-year period.